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ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine whether or not
bimatoprost 0.03% improves satisfaction in patients at least 12 years old with eyelash
hypotrichosis.
STUDY DESIGN: Systematic review of three multicenter, double-masked, randomized, parallel
group studies, all published in English between 2015 and 2016.
DATA SOURCES: All three studies used in this review were researched via PubMed and were
published in peer-reviewed journals.
OUTCOMES MEASURED: Patient satisfaction was measured using the Eyelash Satisfaction
Questionnaire (ESQ) in all three studies.
RESULTS: Wirta et al. (J Clin Aesthet Dermatol. 2015;8:11–20.) found a statistically
significant relationship between bimatoprost 0.03% and satisfaction with a p=0.004. Borchert et
al. (Clin Ophthalmol. 2016;10:419-29. doi:10.2147/OPTH.S89561) did not indicate a p-value but
78.2% of subjects treated with bimatoprost 0.03% and 65% of subjects in the control were found
to have an increase in satisfaction of eyelash growth at the end of the study. The study
conducted by Glaser et al. (Br J Dermatol. 2015;172(5):1384-94.) did not find a statistically
significant relationship between bimatoprost 0.03% and satisfaction with p=0.25.
CONCLUSIONS: The results of these studies show that the objective question remains
inconclusive in regard to increasing patient satisfaction after the use of bimatoprost 0.03% as
only one out of the three studies showed a statistically significant relationship. Further studies
should be conducted with researchers not employed by the pharmaceutical company who
manufactures the product.
KEY WORDS: bimatoprost, eyelash
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INTRODUCTION
Eyelash hypotrichosis is a condition that is characterized by reduced hair growth, specifically
of the eyelashes. Hypotrichosis is often used interchangeably with the term alopecia areata
which is a condition of the skin that causes sudden hair loss in various parts of the body.1 The
presentation of eyelash hypotrichosis is an inadequate amount of hair at the margin of the upper
eyelids while alopecia areata presents as hair loss on the body, scalp, eyebrows or eyelashes.
Eyelashes are considered terminal hair, in which the hair is coarse, thick and pigmented, versus
vellus hair which is the soft, short and non-pigmented hair, such as those found on the face.2 The
function of eyelashes is very versatile. Eyelashes provide a barrier, protecting the eyes from
foreign bodies and perspiration by triggering the corneal reflex if touched. Eyelashes are also
cosmetically appealing, and the length of eyelashes signifies beauty and femininity in most
cultures while increasing the attractiveness of a person.2
Causes of eyelash hypotrichosis include genetics, chemotherapy induced, advanced age or
trauma to the face including trichotillomania.2 Eyelash hypotrichosis is a common side effect
among chemotherapy drugs. Since hair cells are rapidly dividing, chemotherapy drugs destroy
those cells, causing hair loss.3 The prevalence of eyelash hypotrichosis is unknown, although,
chemotherapy induced hair loss, including eyelashes will be the result of approximately sixtyfive percent of patients undergoing chemotherapy.4 As stated previously, eyelashes have a
physical and cosmetic component attached to them and eyelash hypotrichosis or alopecia areata
may lead to a negative impact on the patient’s quality of life including an impairment in psychosocial functioning as well as negatively affecting the self-image of a person.5
Unfortunately, the number of healthcare visits for eyelash hypotrichosis has not been
identified; however, there is an estimated 2.4 million doctor office visits in the United States are
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for alopecia areata.6 The cost of eyelash hypotrichosis has not been identified, but the out-ofpocket costs associated with alopecia areata is approximately $1,354 per year.7 This cost
includes hair appointments, vitamins, insurance deductibles, office visits, transportation and wigs
for patients with alopecia areata.7
To date, there is no known definitive treatment for eyelash hypotrichosis. Additionally, there
is no known cure or FDA-approved treatments for alopecia areata. There are, however, off label
uses for corticosteroids, calcineurin inhibitors, immunotherapies and hair-growth-stimulating
solutions for alopecia areata. 8 Many patients have reported these treatments as ineffective
while some patients could not tolerate the side effects, therefore, needing additional treatment
options.8 Corticosteroids are the most common type of medication prescribed for alopecia
areata, which includes oral, topical and injectable. This treatment worked well for some patients,
but many have stated that corticosteroids worked very little to none.8 Fortunately, for patients
with eyelash hypotrichosis, there is now an FDA-approved treatment, bimatoprost 0.03%.
Bimatoprost is a synthetic prostamide F2 alpha analogue and its use for eyelash hypotrichosis
was empirically discovered in patients being treated with bimatoprost for increased intraocular
pressure in patients with open-angle glaucoma.9 As stated previously, many patients reported the
treatments above were ineffective for alopecia areata, but the same has not been reported for
bimatoprost 0.03%.
OBJECTIVE:
The objective of this systematic review is to determine whether or not bimatoprost 0.03%
improves satisfaction in patients at least 12 years old with eyelash hypotrichosis.
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METHODS
This systematic review analyzes three randomized control trials (RCTs) to assess patient
satisfaction of bimatoprost 0.03% for the treatment of eyelash hypotrichosis compared with a
vehicle in patients at least 12 years old.
All three articles were found through PubMed using the key words bimatoprost and eyelash.
The articles selected for review were published in English and were published in peer-reviewed
journals. Each article was selected based on its relevance to the clinical question and if they
included patient orientated outcomes (POEMS). The inclusion criteria consisted of all articles
being published in English and dated 2008 or later. Studies were excluded from this review if
published in another language other than English, dated before 2008 or if bimatoprost was used
for other indications. All three articles used p-value, EER, CER, ARR, NNT, ABI and RBI
statistics. Please see Table 1 for the outline of demographics and characteristics of each study.
For this selective evidence-based medicine review, the author chose three randomized
control studies (RCTs) that were selected, reviewed and analyzed based on population,
intervention, comparison groups and outcomes measured. This review included a population of
patients at least 12 years of age with idiopathic or chemotherapy induced eyelash hypotrichosis.
The intervention in these studies involved an application of bimatoprost 0.03% ophthalmic
solution to the margin of the upper eyelids. The patients receiving bimatoprost 0.03% were
compared to the experimental group in which patients applied a vehicle to the margin of the
upper eyelids. Each of the three studies measured the satisfaction of the patients in both the
treatment and control group using the Eyelash Satisfaction Questionnaire (ESQ) which is a selfreported assessment of satisfaction.
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Table 1. Demographics & Characteristics of Included Studies
Study
Type
#
Age Inclusion Criteria
Exclusion
Pts (yrs)
Criteria
5
Wirta
Double 130 ≥ 18 ≥ 18 yo w/ chemoIf they did not
(2015)
blind
induced eyelash
have a GEA
RCT
hypotrichosis Tx’d for score of 1 or 2, or
Stage I-IIIA solid
if they did not
tumors w/ curative
have a ESQ score
intent or rcv’d frontof 1 or 2 in
line tx for stage I - II
certain
DLBCL or HL;
categories.
resolution of chemo
Subjects w/
related AE’s except
unequal GEA
for hair loss;
scores for the RT
completed chemo 4and LT
16 wks prior to study eyelashes,
baseline; Had Eastern uncontrolled
Cooperative
systemic disease
Oncology group
or known ocular
performance status of disease or
0 or 1 & no evidence
abnormality.
of mets or anticipated
need for further
chemo during study
period
Borchert Double 65
1212-17 yo Healthy,
Positive Preg
10
blind
17
Chemo or alopecia
test; Gross
(2016)
RCT
areata induced
asymmetry of
eyelash hypotrichosis; eyelash
GEA score 1-3, visual prominence,
acuity of 20/100; IOP uncontrolled
≤20mmhg; completed systemic disease,
chemo 4 wks; chemo trichotillomania
related AE’s
or known ocular
resolved/managed;
disease
11
Glaser
Double 130 ≥ 18 ≥ 18 yo w/ score of 1- Any eye disease
(2015)
blind
2 on GEA and ESQ;
or abnormality;
RCT
visual acuity of
hx of eye surgery
20/100; IOP ≤20
mmhg; Inadequate
eyelashes after
chemo, tx for stage
1,2 or 3a cancer; last
chemo was 4-16wks
prior to baseline,
considered ca free

4

W
/D
7

Interventions

1

Bimatoprost
0.03%

14

Bimatoprost
0.03%

Bimatoprost
0.03%
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OUTCOMES MEASURED
The outcomes measured in this selective evidence-based review were based on patientreported questionnaires that were completed throughout and at the end of the bimatoprost 0.03%
ophthalmic treatment.
In all three studies, patient satisfaction was measured using the Eyelash Satisfaction
Questionnaire (ESQ). This is a patient-reported outcome measure that consists of 23 questions
measured on a five-point scale. The scale included: 1- very much disagree, 2- disagree, 3neutral, 4- agree, 5- very much agree. The 23 questions consisted of three domains which
assessed various outcomes. The Wirta et al.5 study focused on Domain 2 of the ESQ which
assessed satisfaction with subjective attributes of eyelashes such as attractiveness, confidence
and professionalism.11 In this study, subjects were assessed with the ESQ before and after
treatment. In a pediatric study by Borchert et al.,10 only subject’s aged 12-17 assessed their
eyelashes with the ESQ as well. These subjects were evaluated at screening and months 1-5 of
the study.10 The last study by Glaser et al.11 also measured patient satisfaction using the ESQ
five-point scale Domain 2 before and after treatment.
RESULTS
This systematic review analyzed three randomized control studies to determine if
bimatoprost 0.03% can increase satisfaction in patients at least 12 years old who have eyelash
hypotrichosis. Each study consisted of a treatment group with bimatoprost 0.03% applied to the
upper eyelid margins and a control group with a vehicle applied to the upper eyelid margins.
In the Wirta et al.5 study, 130 patients with chemotherapy induced eyelash hypotrichosis
were randomized with a web response system of an automatic interactive voice to either
bimatoprost 0.03% (n=96) or a vehicle group (n=34). Patients, investigators and their staff were
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blind to treatment assignment for the entire treatment period. Each subject was asked to place
one drop of treatment or vehicle to a sterile, single-use applicator and then brush it on the upper
eyelid margins once every evening. Excluded subjects were those with unequal Global Eyelash
Assessment (GEA) scores for the left and right eyelashes, uncontrolled systemic disease or
known ocular disease. Eye examinations such as intraocular pressure and iris color were
conducted throughout the study. Conjunctival hyperemia was the most common adverse
reaction of bimatoprost, followed by punctate keratitis, upper respiratory tract infection and eye
pruritus, respectively. The study reported one death following the first administration of
bimatoprost, but investigators attribute this due to an elective surgery and not related to the study
medication.5
Wirta et al.5 compared baseline and 6 months ESQ Domain 2 scores of subjects and
increased satisfaction was considered if there was a ≥ 3-point improvement. At the end of the 6
months, Wirta et al.5 found that there was an increase in satisfaction in 46.9% (46 patients)
versus 18.2% (6 patients) for bimatoprost 0.03% and vehicle, respectively. The p-value was
considered to be statistically significant at p=0.004 and NNT was calculated to be 4. Table 2
includes detailed calculations for this study.
Table 2. NNT Calculations For Satisfaction of Bimatoprost 0.03% To Improve Eyelash
Hypotrichosis By Wirta et al.5
CER
EER
Relative Benefit
Absolute Benefit Number Needed P-value
Increase (RBI)
Increase (ABI)
To Treat (NNT)
0.182
0.469= 1.576
0.287
4
0.004
= 18.2% 46.9%

Borchert et al.10 studied 62 pediatrics aged 12-17 years old with eyelash hypotrichosis
who were randomized 2:1 to either receive bimatoprost 0.03% (n=42) or vehicle (n=20).
Patients, investigators and their staff were blind to treatment assignment for the entire treatment
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period of 5 months. Subjects or their guardians were instructed to place one drop of treatment or
vehicle to a sterile, single-use applicator and then brush it on the upper eyelid margins once
every evening. Subjects were excluded from this study if there was gross asymmetry of eyelash
prominence between right and left eyes, uncontrolled systemic disease, suspected or known
trichotillomania or ocular disease appreciated. Adverse effects were monitored at each study
entry and physical exams performed including eye examinations of IOP, visual acuity and iris
color at baseline, and months 1 and 4.10
This study used Pearson’s chi-square and dichotomized the ESQ score responses into two
groups: satisfied and not satisfied/neutral.10 The results showed that mean scores improved from
baseline in both treatment groups for satisfaction.10 This study showed that 78.2% (33 patients)
of subjects in the treatment group were satisfied versus 65% (13 patients) of subjects in the
control group. There was no p-value calculated for subject satisfaction and NNT was calculated
to be 8. Table 3 includes detailed calculations for review.
Table 3. NNT Calculations For Satisfaction of Bimatoprost 0.03% To Improve Eyelash
Hypotrichosis By Borchert et al.10
CER
EER
Relative Benefit
Absolute
Number Needed P-value
Increase (RBI)
Benefit increase To Treat (NNT)
(ABI)
0.65
0.785= 0.207
0.135
8
Not
= 65%
78.5%
calculated
Glaser et al.11 analyzed 129 subjects with chemotherapy-induced eyelash hypotrichosis
who were randomized to either receive bimatoprost 0.03% (n=96) or vehicle (n=33). All
patients, investigators and staff were blind to treatment assignment for the entire study. Subjects
were instructed to place one drop of treatment or vehicle to a sterile, single-use applicator and
then apply it to the upper eyelid margins once every evening. In this study, subjects were
excluded if they had any eye abnormality or disease or a history of eye surgery. Primary efficacy
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was based on at least a 3-point increase from baseline in the total score for ESQ domain 2.
Glaser et al.11 found an increase in satisfaction in 47.9% (46 patients) versus 36.4% (12 patients)
for bimatoprost 0.03% and vehicle, respectively. The p-value was considered to not be
statistically significant at p=0.25 and NNT was calculated to be 9. Table 4 includes detailed
calculations.
Table 4. NNT Calculations For Satisfaction of Bimatoprost 0.03% To Improve Eyelash
Hypotrichosis By Glaser et al.11
CER
EER
Relative Benefit
Absolute Benefit Number Needed PIncrease (RBI)
Increase (ABI)
To Treat (NNT) value
0.365
0.479
0.315
0.115
9
0.25
=36.5% =47.9%

DISCUSSION
This systematic review analyzes the results of bimatoprost 0.03% for patients with
eyelash hypotrichosis. Only one of the three studies show statistical significance for the use of
bimatoprost 0.03% in patients with eyelash hypotrichosis. In the Wirta et al.5 study, p= 0.004 is
statistically significant and suggestive of increased satisfaction of eyelash growth with the use of
bimatoprost 0.03%. In the Borchert et al.10 study, no p-value was calculated, but 78.2% of
subjects in the experimental group and 65% of subjects in the control group expressed
satisfaction after treatment of bimatoprost 0.03%. These percentages were used to calculate the
NNT. Based upon no provided p-value and the small NNT compared against a small sample
size, there is not enough information to conclude whether or not this study led patients to
increased satisfaction. On the other hand, the Glaser et al.11 study was found to not be
statistically significant with p=0.25.
Currently, bimatoprost 0.03% is marketed by only one pharmaceutical company,
Allergan which is sold under the name, Latisse. Since Latisse is used for cosmetic purposes
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only, insurance companies do not cover the product. Patients can purchase Latisse out of pocket
with a prescription for a monthly cost of approximately $120.00.12 At this cost, most patients
may not be able to afford this monthly price. According to Banaszek,12 patients with glaucoma
using Lumigan, should not use Latisse as it would double the dose of bimatoprost 0.03%. This is
because Lumigan and Latisse are the same exact drug, just packaged and administered
differently.12
Acknowledging limitations to these studies is very important. In all three studies, subjects
were instructed to apply bimatoprost 0.03% every evening in the same fashion. If subjects did
not follow these instructions closely, the results could have been skewed. In the Wirta et al.5
study, 125 subjects out of a total of 130 subjects had a history of breast cancer. Since most
subjects in the Wirta et al.5 study were found to have breast cancer, the results of this study may
have had a different outcome if the type of cancer was more diverse. Additionally, there is
overlap between the researchers for all three studies and this may limit the generalizability of the
results.
CONCLUSIONS
The results from this selective evidence-based review indicate that bimatoprost 0.03%
increases patient satisfaction in only one out of the three studies. Based upon this, the answer to
the objective question remains inconclusive in regard to increasing patient satisfaction and
further research should be conducted. The outcomes could have been affected by drug
adherence and correct application of bimatoprost 0.03%. Subjects or their parents were expected
to apply the treatment every evening in a specific fashion. The outcomes may have also been
affected by the researchers as each study disclosed that they were consultants, investigators or
employees of Allergan, the pharmaceutical company that produces Latisse. Future research of
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bimatoprost 0.03% for eyelash hypotrichosis should be conducted without any affiliation to
Allergan pharmaceuticals to eliminate any bias that may occur.
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